Consensus Foghorn Therapeutics Inc.

Equities

FHTX

US3441741077

Real-time Estimate Cboe BZX Other stock markets 09:37:14 2024-04-25 am EDT			5-day change	1st Jan Change
4.82 ^USD	-7.49%		-9.86%	-19.22%

Apr. 16	Foghorn Therapeutics Names Kristian Humer CFO	MT
Apr. 16	Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer	CI

Evolution of the average Target Price on Foghorn Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

d213beb655c9275df5ef4d8993.-VTK3kYV8mMbL-EXS0f9nALn-J4UXRElwiAFm-WtS64.vyaCvD5SighiaKN6CSWp0kHeksRdZHNV8VBC6qb4cpmaHa-wN0SiO1l7kg~3d5ab3c9d47f0cccee17bc57b3824892

Analyst Recommendations on Foghorn Therapeutics Inc.

Morgan Stanley Adjusts Price Target on Foghorn Therapeutics to $6 From $10, Maintains Equalweight Rating	Nov. 13	MT
Morgan Stanley Adjusts Price Target on Foghorn Therapeutics to $10 From $13, Maintains Equal-Weight Rating	23-07-06	MT
Goldman Sachs Cuts Foghorn Therapeutics' Price Target to $19 From $21, Keeps Buy Rating	23-06-29	MT
Wedbush Trims Foghorn Therapeutics Price Target to $13 From $14, Maintains Outperform Rating	23-06-28	MT
HC Wainwright Adjusts Price Target on Foghorn Therapeutics to $20 From $25, Keeps Buy Rating	23-05-09	MT
Wedbush Trims Foghorn Therapeutics' Price Target to $14 From $15, Tweaks Financing Assumptions; Keeps Outperform Rating	23-05-09	MT
BMO Capital Adjusts Price Target on Foghorn Therapeutics to $19 From $20, Maintains Outperform Rating	23-04-25	MT
Wedbush Lowers Foghorn Therapeutics' Price Target to $15 From $20 After Pause in Enrollment for FHD-609 Program, Keeps Outperform Rating	23-04-25	MT
BofA Securities Initiates Coverage on Foghorn Therapeutics With Buy Rating, $10 Price Target	23-03-28	MT
Wedbush Lowers Foghorn Therapeutics's Price Target to $20 From $25, Tweaks Timing Around Programs; Keeps Outperform Rating	23-03-10	MT
BMO Capital Starts Foghorn Therapeutics at Outperform With $20 Price Target	23-01-05	MT
Morgan Stanley Adjusts Foghorn Therapeutics Price Target to $14 From $15, Maintains Equal Weight Rating	22-11-21	MT
Morgan Stanley Downgrades Foghorn Therapeutics to Equalweight From Overweight, Lowers Price Target to $15 From $25	22-08-24	MT
ANALYST RECOMMENDATIONS : Intuit, XPeng, Rio Tinto, Prologis, Charter Communications...	22-08-24
Morgan Stanley Downgrades Foghorn Therapeutics to Equalweight From Overweight, Cuts Price Target to $15 From $25	22-08-23	MT
Wedbush Cuts Price Target on Foghorn Therapeutics to $25 From $32, Citing FHD-286 Clinical Hold; Outperform Rating Kept	22-08-23	MT
Wall Street Stabilizes Pre-Bell After Slump Fueled by Rate Hike Concerns	22-08-23	MT
HC Wainwright Increases Foghorn Therapeutics' Price Target to $25 From $18, Maintains Buy Rating	22-08-10	MT
Goldman Sachs Adjusts Foghorn Therapeutics' Price Target to $21 from $30, Keeps Buy Rating	22-05-24	MT
Morgan Stanley Adjusts Price Target for Foghorn Therapeutics to $25 From $26, Maintains Overweight Rating	22-05-23	MT
Wall Street Set for Gains as China Rate Cut Boosts Sentiment	22-05-20	MT
HC Wainwright Adjusts Foghorn Therapeutics' Price Target to $18 From $25, Keeps Buy Rating	22-05-20	MT
Wedbush Adds Outperform-Rated Foghorn Therapeutics to Best Ideas List; Price Target is $32	22-03-11	MT
Morgan Stanley Raises Price Target for Foghorn Therapeutics to $26 From $23, Maintains Overweight Rating	21-12-15	MT
Wedbush Raises Price Target for Foghorn Therapeutics to $32 From $24 on Eli Lilly Collaboration, Maintains Outperform Rating	21-12-13	MT